Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | AKT2 | P31751 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449933 | 0.90 | JAK2 (0.47) | CCR1CCR8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6452524 | 0.85 | DCUN1D1 (0.50) | CCR1CCR8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13377809 | 0.84 | CCR1 (0.54) | CCR1CCR8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6449632 | 0.82 | JAK2 (0.56) | CCR1CCR8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18807016 | 0.76 | CCR1 (0.62) | CCR1CCR8METAP2TGFBR1HCRTR1 | |
| SCHEMBL6454147 | 0.75 | MEN1 (0.41) | CCR1CCR8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6448909 | 0.75 | GRK6 (0.49) | NPC1RAB9ATGFBR1NR1H2NR1H3 | |
| SCHEMBL6452058 | 0.75 | NR1H2 (0.46) | NPC1RAB9ASMN1; SMN2TGFBR1NR1H2 | |
| SCHEMBL6451236 | 0.75 | NR1H2 (0.59) | CCR1CCR8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7049722 | 0.75 | TGFBR1 (0.53) | CCR1CCR8NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | CCR1 128/4885CCR8 124/4885NPC1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.